1
|
Xiong T, Li J, Chen F, Zhang F. PCAT-1: A Novel Oncogenic Long Non-Coding RNA in Human Cancers. Int J Biol Sci 2019; 15:847-856. [PMID: 30906215 PMCID: PMC6429018 DOI: 10.7150/ijbs.30970] [Citation(s) in RCA: 34] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2018] [Accepted: 01/17/2019] [Indexed: 02/06/2023] Open
Abstract
Long non-coding RNAs (lncRNAs) are transcripts longer than 200 nucleotides (nts) without obvious protein coding potential. lncRNAs act as multiple roles in biological processes of diseases, especially carcinomas. Prostate cancer associated transcript-1 (PCAT-1) is an oncogenic lncRNA that identified by RNA-Sequence in prostate cancer. High expression of PCAT-1 is observed in different types of cancers, including prostate cancer, colorectal cancer, hepatocellular cancer and gastric cancer. High expressed PCAT-1 is correlated with poor overall survival. Furthermore, PCAT-1 regulates cancer cell proliferation, apoptosis, migration and invasion. Additionally, PCAT-1 is involved in EMT and Wnt/β-catenin-signaling pathway. In this review, we focus on the implication of PCAT-1 in human cancers.
Collapse
Affiliation(s)
- Tiefu Xiong
- The Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Institute of Urology, Peking University Shenzhen Hospital, Shenzhen 518036
| | - Jianfa Li
- The Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Institute of Urology, Peking University Shenzhen Hospital, Shenzhen 518036
| | - Fangfang Chen
- The Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Institute of Urology, Peking University Shenzhen Hospital, Shenzhen 518036
| | - Fangting Zhang
- The Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Institute of Urology, Peking University Shenzhen Hospital, Shenzhen 518036
| |
Collapse
|
2
|
Lv C, Zhang Z, Zhao T, Han MF, Jia DP, Su LZ, Huang F, Wang FZ, Fang FF, Li B. The anti-tumour effect of Mel and its role in autophagy in human hepatocellular carcinoma cells. Am J Transl Res 2019; 11:931-941. [PMID: 30899392 PMCID: PMC6413251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2017] [Accepted: 07/07/2017] [Indexed: 06/09/2023]
Abstract
Melittin (Mel), a major component of venom of honey bee (Apismellifera), has various biological effects. Recent researches have reported the anti-tumor activity of Mel in various human cancers, including hepatocellular carcinoma (HCC). In this study, we aimed to further discuss the role of Mel in HCC and investigate the correlation of autophagy with the effect of Mel in HCC cells. Methyl thiazolyl tetrazolium (MTT) assay and flow cytometry were used to detect the viability and apoptosis of HCC cells, respectively. To examine the changes of autophagy in HCC cells treated with Mel, transmission electronmicroscope (TEM) and immunofluorescence detection were adopted. Finally, we used western blot method to detect the changes of pivotal proteins in autophagy and mitochondrial apoptotic pathways. The results of MTT assay and flow cytometry revealed that Mel could suppress the cell viability and promote the apoptosis of HCC cells. Autophagy could be induced by the treatment with Mel in HCC cells. The inhibition of autophagy by chloroquine (CQ) contributed to the enhanced anti-tumor effect of Mel, but autophagy induction by RAPA decreased Mel effect in HCC cells. Mel was closely associated with the expression of proteins in mitochondrial apoptotic pathway. In summary, Mel could induce the autophagy of HCC cells, and the autophagy might offer protection against apoptosis in HCC. Mel might suppress the tumor through activating mitochondrial apoptotic pathway.
Collapse
Affiliation(s)
- Can Lv
- Department of Traditional Chinese Medicine, Changhai Hospital, Second Military Medical UniversityShanghai 200433, P. R. China
| | - Zhan Zhang
- Department of Traditional Chinese Medicine, Changhai Hospital, Second Military Medical UniversityShanghai 200433, P. R. China
| | - Tong Zhao
- Department of Traditional Chinese Medicine, Changhai Hospital, Second Military Medical UniversityShanghai 200433, P. R. China
| | - Meng-fei Han
- Department of Traditional Chinese Medicine, Changhai Hospital, Second Military Medical UniversityShanghai 200433, P. R. China
| | - Da-peng Jia
- Shanghai University of Traditional Chinese MedicineShanghai 201203, P. R. China
| | - Ling-zi Su
- Shanghai University of Traditional Chinese MedicineShanghai 201203, P. R. China
| | - Feng Huang
- Department of Traditional Chinese Medicine, Changhai Hospital, Second Military Medical UniversityShanghai 200433, P. R. China
| | - Fu-zhe Wang
- Department of Traditional Chinese Medicine, Changhai Hospital, Second Military Medical UniversityShanghai 200433, P. R. China
| | - Fan-Fu Fang
- Department of Traditional Chinese Medicine, Changhai Hospital, Second Military Medical UniversityShanghai 200433, P. R. China
| | - Bai Li
- Department of Traditional Chinese Medicine, Changhai Hospital, Second Military Medical UniversityShanghai 200433, P. R. China
| |
Collapse
|
3
|
Zhang F, Li J, Xiao H, Zou Y, Liu Y, Huang W. AFAP1-AS1: A novel oncogenic long non-coding RNA in human cancers. Cell Prolif 2018; 51:e12397. [PMID: 29057544 PMCID: PMC6528908 DOI: 10.1111/cpr.12397] [Citation(s) in RCA: 46] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2017] [Accepted: 09/24/2017] [Indexed: 02/05/2023] Open
Abstract
Long non-coding RNAs (lncRNAs), a group of non-protein-coding RNAs with more than 200 nucleotides in length, are involved in multiple biological processes, such as the proliferation, apoptosis, migration and invasion. Moreover, numerous studies have shown that lncRNAs play important roles as oncogenes or tumour suppressor genes in human cancers. In this paper, we concentrate on actin filament-associated protein 1-antisense RNA 1 (AFAP1-AS1), a well-known long non-coding RNA that is overexpressed in various tumour tissues and cell lines, including oesophageal cancer, pancreatic ductal adenocarcinoma, nasopharyngeal carcinoma, lung cancer, hepatocellular carcinoma, ovarian cancer, colorectal cancer, biliary tract cancer and gastric cancer. Moreover, high expression of AFAP1-AS1 was associated with the clinicopathological features and cancer progression. In this review, we sum up the current studies on the characteristics of AFAP1-AS1 in the biological function and mechanism of human cancers.
Collapse
Affiliation(s)
- Fuyou Zhang
- Key Laboratory of Medical Reprogramming TechnologyShenzhen Second People's HospitalFirst Affiliated Hospital of Shenzhen UniversityShenzhen518039Guangdong ProvinceChina
| | - Jianfa Li
- Key Laboratory of Medical Reprogramming TechnologyShenzhen Second People's HospitalFirst Affiliated Hospital of Shenzhen UniversityShenzhen518039Guangdong ProvinceChina
- Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and GeneticsInstitute of UrologyPeking University Shenzhen HospitalShenzhen PKU‐HKUST Medical CenterShenzhen518036China
| | - Huizhong Xiao
- Key Laboratory of Medical Reprogramming TechnologyShenzhen Second People's HospitalFirst Affiliated Hospital of Shenzhen UniversityShenzhen518039Guangdong ProvinceChina
- University of South ChinaHengyangHunan421001China
| | - Yifan Zou
- Key Laboratory of Medical Reprogramming TechnologyShenzhen Second People's HospitalFirst Affiliated Hospital of Shenzhen UniversityShenzhen518039Guangdong ProvinceChina
- Shantou University Medical CollegeShantou515041Guangdong ProvinceChina
| | - Yuchen Liu
- Key Laboratory of Medical Reprogramming TechnologyShenzhen Second People's HospitalFirst Affiliated Hospital of Shenzhen UniversityShenzhen518039Guangdong ProvinceChina
| | - Weiren Huang
- Key Laboratory of Medical Reprogramming TechnologyShenzhen Second People's HospitalFirst Affiliated Hospital of Shenzhen UniversityShenzhen518039Guangdong ProvinceChina
- University of South ChinaHengyangHunan421001China
- Shantou University Medical CollegeShantou515041Guangdong ProvinceChina
| |
Collapse
|
4
|
Xiao H, Zhang F, Zou Y, Li J, Liu Y, Huang W. The Function and Mechanism of Long Non-coding RNA-ATB in Cancers. Front Physiol 2018; 9:321. [PMID: 29692736 PMCID: PMC5902489 DOI: 10.3389/fphys.2018.00321] [Citation(s) in RCA: 42] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2017] [Accepted: 03/15/2018] [Indexed: 02/05/2023] Open
Abstract
Long non-coding RNAs (lncRNAs) are a class of transcriptional RNA molecules with a length of greater than 200 nucleotides that function as regulatory factors in many human diseases. Studies have shown that lncRNAs are involved in multiple cellular processes, including proliferation, apoptosis, migration, and invasion. In this report, a long non-coding RNA-ATB that is overexpressed in various tumor tissues and cell lines was investigated. Recent evidence suggests that ATB is dysfunctional in a variety of cancers, including hepatocellular carcinoma, gastric cancer (GC), colorectal cancer (CRC), breast cancer (BC), prostate cancer, renal cell carcinoma, non-small cell lung cancer (NSCLC), pancreatic cancer, osteosarcoma, and glioma. The high expression of ATB is associated with clinicopathological features of cancer patients. In addition, overexpression of lncRNA-ATB can promote tumor proliferation, migration, and invasion. LncRNA-ATB induces epithelial-mesenchymal transition (EMT) by competitively binding to miRNAs, thus promoting tumor progression. Biological functions and mechanisms of ATB in human cancers are discussed here, concluding that lncRNA-ATB may provide a new biomarker for use in diagnosis and prognosis of cancer.
Collapse
Affiliation(s)
- Huizhong Xiao
- Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen, China
- University of South China, Hengyang, China
| | - Fuyou Zhang
- Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen, China
| | - Yifan Zou
- Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen, China
- Shantou University Medical College, Shantou, China
| | - Jianfa Li
- Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen, China
- Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Institute of Urology, Peking University Shenzhen Hospital, Shenzhen, PKU-HKUST Medical Center, Shenzhen, China
| | - Yuchen Liu
- Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen, China
- *Correspondence: Yuchen Liu
| | - Weiren Huang
- Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen, China
- University of South China, Hengyang, China
- Shantou University Medical College, Shantou, China
- Weiren Huang
| |
Collapse
|